This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar content in this book Download to citation manager Rights & Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Vose, J. M. Search for Related Content PubMed Articles by Vose, J. M.

The International Peripheral T-Cell and Natural Killer/T-Cell Lymphoma Study: What Have We Learned?

From the Neumann M. And Mildred E. Harris Professor of Medicine, Chief, Section of Hematology/Oncology, University of Nebraska Medical Center, 987680 Nebraska Medical Center, Omaha, NE-7680

Authors’ disclosures of potential conflicts of interest are found at the end of this article.

Address reprint requests to: Julie M. Vose, MD, Neumann M. And Mildred E. Harris Professor of Medicine, Chief, Section of Hematology/Oncology, University of Nebraska Medical Center, 987680 Nebraska Medical Center, Omaha, NE 68198-7680; e-mail: jmvose{at}unmc.edu

Overview: The importance of immunophenotype for the outcome of patients with aggressive lymphoma has only recently been incorporated into pathologic classifications, after it was recognized that these patients had specific clinical-pathologic entities and often experienced a poor outcome with standard therapies. The International Peripheral T-cell and Natural Killer (NK)/T-cell Lymphoma Study included 1,314 patients with these entities from 22 sites worldwide. The clinical characteristics, pathologic review, and outcomes are evaluated for these patients and compared between different geographic areas. Based on these results, further identification of subtypes with expected unfavorable outcomes will assist physicians in the development of optimal future therapies.